Research Program Overview
This ongoing study investigates how specific serum markers relate to the progression of cervical spondylotic myelopathy (CSM), a common condition causing spinal cord compression and neurological deficits in older adults. We are focusing on the neural cell adhesion molecule (NCAM) to understand its role in CSM stages and its potential to guide treatment decisions.
Our biomarker research program employs advanced molecular biology techniques and clinical correlation studies to identify, validate, and characterize protein markers that can serve as diagnostic, prognostic, and therapeutic monitoring tools for spine diseases. This approach represents a paradigm shift toward precision medicine in spine care, enabling personalized treatment strategies based on individual biomarker profiles.
Research Impact
Our biomarker research program has achieved significant milestones:
- 420+ peer-reviewed publications advancing spine research and biomarker discovery
- $600,000+ in active research funding supporting ongoing biomarker studies
- Clinical Translation focus on developing clinically applicable tests that can guide treatment decisions and improve patient outcomes
Clinical Translation
Our biomarker research focuses on developing clinically applicable tests that can guide treatment decisions and improve patient outcomes. We work toward establishing standardized protocols that can be implemented in routine clinical practice to enhance diagnostic accuracy and personalized treatment planning for spine disease patients.
Research Inquiries Collaboration Opportunities
Mission
To investigate specific serum markers that relate to the progression of cervical spondylotic myelopathy (CSM) and other spine diseases, focusing on the neural cell adhesion molecule (NCAM) to understand its role in disease stages and guide treatment decisions for improved patient outcomes.
Primary Research Areas
NCAM Analysis
Neural cell adhesion molecule analysis for cervical spondylotic myelopathy progression markers
Serum Biomarkers
Identification and validation of serum biomarkers for disease stage correlation studies
Treatment Monitoring
Development of biomarkers for treatment response monitoring and precision medicine applications
Inflammatory Markers
Analysis of inflammatory cascade biomarkers and neurodegeneration protein markers
Spinal Cord Indicators
Development of spinal cord compression indicators and prognostic biomarker panels
Clinical Translation
Translation of research findings into clinically applicable diagnostic and treatment tools
Research Methodology
Our research program utilizes state-of-the-art proteomics and molecular biology techniques including enzyme-linked immunosorbent assays (ELISA), mass spectrometry, and multiplex protein analysis platforms. We employ rigorous study designs with appropriate controls and statistical power calculations to ensure reliable biomarker discovery and validation. Clinical correlation studies involve comprehensive patient assessment including neurological examination, functional outcome measures, and advanced imaging studies. Longitudinal sample collection protocols enable tracking of biomarker changes over time and correlation with disease progression and treatment responses. We collaborate with clinical laboratories to establish standardized assay protocols for future clinical implementation.
Current Initiatives
NCAM in Cervical Myelopathy Study
Ongoing Comprehensive analysis of neural cell adhesion molecule levels in patients with different stages of cervical spondylotic myelopathy to establish diagnostic and prognostic utility.
Biomarker-Guided Treatment Selection
In Development Development of algorithms that incorporate biomarker profiles to optimize timing and selection of surgical versus conservative treatment approaches for spine disease patients.
Multi-Biomarker Panel Development
Planning Phase Creation of comprehensive biomarker panels that combine multiple protein markers to improve diagnostic accuracy and prognostic capability beyond single-marker approaches.
